Updated time: 2024-02-17 08:58:57
28A-1090903
2020-09-22
TW I829014、USP Pending
CLEC2 mediates SARS-CoV-2 and H5N1-induced platelet activation. Furthermore, CLEC2.Fc binds to SARS-CoV-2 RBD and blocks the SARS-CoV-2-induced NETosis/inflammation in vitro, moreover, CLEC2.Fc has prophylactic and therapeutic effects of inflammation, thrombosis and pulmonary fibrosis in SARS-CoV-2-infected mice . CLEC2.Fc also decreases the weight loss and increases the survival rate in H5N1-challenged mice. Therefore, we would like to claim that CLEC2.Fc can be a potent therapeutic agent for CLEC2-mediated inflammatory disease and immunothrombosis.
- We use molecular modeling to identify the interaction regions between SARS-CoV2-RBD and CLEC2, and we find the interaction domain of SARS-CoV2-RBD is distinct from that with. ACE2.
- We have established the binding assay between SARS-CoV-2 and CLEC2 interaction.
- Treatment of systemic intravascular coagulopathy and inflammation in COVID-19 patients.
- Treatment of systemic infection caused by SARS-CoV-2, H5N1 influenza virus-induced systemic inflammation.
- Treatment of inflammatory diseases caused by CLEC2 endogenous and exogenous ligands.
Shie-Liang Hsieh、Pei-Shan Sung
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

CLEC2 inhibitors for the treatment of CLEC2-mediated inflammatory disease and immunothrombosis